---
title: "SVRA.US (SVRA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SVRA.US/news.md"
symbol: "SVRA.US"
name: "SVRA.US"
parent: "https://longbridge.com/en/quote/SVRA.US.md"
datetime: "2026-05-20T18:56:54.866Z"
locales:
  - [en](https://longbridge.com/en/quote/SVRA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SVRA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SVRA.US/news.md)
---

# SVRA.US (SVRA.US) — Related News

### [Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News](https://longbridge.com/en/news/287062772.md)
*2026-05-20T04:15:35.000Z*
> Savara presented new biomarker data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for aut

### [Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News](https://longbridge.com/en/news/286952843.md)
*2026-05-19T10:15:28.000Z*
> Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Ext

### [Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | SVRA Stock News](https://longbridge.com/en/news/286808518.md)
*2026-05-18T10:55:32.000Z*
> Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution

### [LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)](https://longbridge.com/en/news/286648897.md)
*2026-05-16T14:36:21.000Z*
> LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Savara (SVRA) with a price target of $9.00. Th

### [Savaria Improves Earnings per Share by 82% Over Q1 2025](https://longbridge.com/en/news/285443752.md)
*2026-05-06T21:07:13.000Z*
> In Laval, Quebec on May 6, 2026, Savaria Corporation, a major player in the accessibility sector, shared its performance

### [Savaria (SIS) Receives a Buy from Stifel Nicolaus](https://longbridge.com/en/news/284817763.md)
*2026-04-30T18:05:18.000Z*
> In a recent report, Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Savaria (SIS) with a price target 

### [US High Growth Tech Stocks To Watch](https://longbridge.com/en/news/284256218.md)
*2026-04-27T18:00:03.000Z*
> The US market has seen a 30% rise over the past year, with earnings expected to grow by 16% annually. Key high-growth te